FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a KMT2A Translocation By Ogkologos - December 10, 2024 659 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AUGMENT-101 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR EMA Recommends Granting a Marketing Authorisation for a Biosimilar Bevacizumab, Onbevzi November 23, 2020 For Cancer Screening, COVID-19 Pandemic Creates Obstacles, Opportunities March 10, 2021 Multiple Myeloma Awareness Month: Inequity and Disparities in Multiple Myeloma Diagnosis,... March 1, 2021 Pivotal Role of the Institutional Molecular Tumour Board in Evaluating the... September 10, 2021 Load more HOT NEWS Patients with Early-Onset CRC More Often Diagnosed at Advanced Stage of... Pleural Effusion Emerges as a Negative Prognostic Factor for Immune Checkpoint... Failed Alzheimer’s Drug Might Boost CAR T-Cell Therapy for Multiple Myeloma Medicare Open Enrollment Starts Tomorrow!
